Amylyx Pharmaceuticals Inc
NASDAQ:AMLX
Amylyx Pharmaceuticals Inc
Net Issuance of Debt
Amylyx Pharmaceuticals Inc
Net Issuance of Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Net Issuance of Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
Amylyx Pharmaceuticals Inc
NASDAQ:AMLX
|
Net Issuance of Debt
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
Johnson & Johnson
NYSE:JNJ
|
Net Issuance of Debt
$8.4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
40%
|
||
Bristol-Myers Squibb Co
NYSE:BMY
|
Net Issuance of Debt
$12.6B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-7%
|
CAGR 10-Years
37%
|
||
Pfizer Inc
NYSE:PFE
|
Net Issuance of Debt
$4.2B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-16%
|
CAGR 10-Years
15%
|
||
Merck & Co Inc
NYSE:MRK
|
Net Issuance of Debt
$2.8B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
2%
|
CAGR 10-Years
7%
|
||
Eli Lilly and Co
NYSE:LLY
|
Net Issuance of Debt
$10.5B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
16%
|
CAGR 10-Years
45%
|
Amylyx Pharmaceuticals Inc
Glance View
Amylyx Pharmaceuticals, Inc. operates as a biopharmaceutical company, which provides disease-modifying solutions for neurodegenerative diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 205 full-time employees. The company went IPO on 2022-01-07. The firm is developing therapies for treatment paradigm for amyotrophic lateral sclerosis (ALS), and range of neurodegenerative diseases by keeping neurons alive. The firm is pursuing commercialization of its product candidate, AMX0035. AMX0035 is an investigational product comprised of two complementary active agents, sodium phenylbutyrate (PB) and taurursodiol (TURSO) also known as ursodoxicoltaurine. AMX0035 is designed to target the endoplasmic reticulum and mitochondrial-dependent neuronal degeneration pathways in ALS and other neurodegenerative diseases. AMX0035 keep neurons alive under a variety of different conditions and stresses, including in in vitro models of neurodegeneration, endoplasmic reticulum stress, mitochondrial dysfunction, oxidative stress and disease-specific models of a variety of other conditions, as well as in vivo models of Alzheimer’s Disease (AD) and multiple sclerosis.
See Also
What is Amylyx Pharmaceuticals Inc's Net Issuance of Debt?
Net Issuance of Debt
0
USD
Based on the financial report for Dec 31, 2023, Amylyx Pharmaceuticals Inc's Net Issuance of Debt amounts to 0 USD.